ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

Pembrolizumab plus axitinib prolongs survival in advanced renal cell carcinoma

SEC Filing – ALX Oncology

Exploring immunotherapy in colorectal cancer, Journal of Hematology & Oncology

Exploring immunotherapy in colorectal cancer, Journal of Hematology & Oncology

Immunotherapy for head and neck cancer: Present and future - ScienceDirect

mrus-10k_20211231.htm

Frontiers Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

IJMS, Free Full-Text

Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis - ScienceDirect

Immunotherapy-based treatment of Hodgkin lymphoma: What is new?

Frontiers Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer

Clinical Trial Results National Cancer Institute

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations - ScienceDirect

Targeted therapy for breast cancer: An overview of drug classes and outcomes - ScienceDirect